France Oral Anti-Diabetic Drug Market Size and Share
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2019 - 2023 |
| CAGR | 4.00% |
Major Players
*Disclaimer: Major Players sorted in no particular order |
France Oral Anti-Diabetic Drug Market Analysis by Mordor Intelligence
The France Oral Anti-Diabetic Drug Market is expected to register a CAGR of greater than 4% during the forecast period.
Diabetes mellitus was one of the most important risk factors for a severe course of COVID-19. This risk was thought to be impacted by numerous characteristics that are common in diabetes mellitus. Age, proinflammatory and hypercoagulable state, hyperglycemia, hypertension, cardiovascular disease, chronic renal disease, and obesity are all factors. During the COVID-19 pandemic, diabetes was early identified as a risk factor for poor outcomes. As a result, controlling or postponing instances of type 2 diabetes has become more crucial than ever. Diabetic medications were considered prospective treatments for diabetic people infected with SARS-CoV-2 during the COVID-19 pandemic.
Diabetes meds are medications designed to stabilize and manage blood glucose levels in diabetics. Diabetes medications are often used to treat the disease. Diabetes medications are classified into several categories. Each type of drug has a unique method of action for lowering blood sugar. A medication may function by inducing the pancreas to produce and release more insulin, reducing the liver's capacity to produce and release sugar, inhibiting the action of enzymes in the intestines that break down carbs, and many other mechanisms. It also raises cell sensitivity to insulin, decreasing the kidneys' ability to take in sugar and increasing the quantity of sugar exiting the body in urine.
Diabetes is the greatest frequency of any chronic ailment covered entirely by France's statutory health insurance (SHI), and the number of insured patients has more than quadrupled in the last decade. Diabetes is becoming more common among people of all ages in France, which can be ascribed to an increasingly obese population, bad diets, and sedentary lifestyles. Thus, rising diabetes and obesity rates, increased knowledge of diabetic care, increased healthcare spending, and technological improvements are a few of the drivers driving the France oral anti-diabetes drugs market.
France Oral Anti-Diabetic Drug Market Trends and Insights
Dipeptidyl peptidase - 4 (DPP-4) inhibitors Segment Occupied the Highest Market Share in France’s Oral Anti-Diabetic Drugs Market in the current year.
In terms of revenue, the DPP-4 inhibitors segment is anticipated to lead the France Oral Anti-Diabetic Drugs Market and post a CAGR of over 3% during the forecast year.
DPP-4 inhibitors are a type of medication that lowers high blood glucose levels, and treats type 2 diabetes. Dipeptidyl-peptidase 4 inhibitors have glucose regulation effects by extending the effects of GLP-1 and GIP, resulting in increased glucose-mediated insulin and suppression of glucagon production. Aside from DPP4 inhibitors' glucose-lowering characteristics, new data shows that incretin-based medicines may also benefit inflammation, cardiovascular and hepatic health, sleep, and the central nervous system.
Oral anti-diabetic drugs are available across France and are indicated for usage when type 2 diabetes therapy must be escalated in conjunction with lifestyle modification. Because of their wide variety of effectiveness, safety, and modes of action, oral medicines are often the first drugs utilized in the treatment of type 2 diabetes. Anti-diabetic medications assist diabetic patients in controlling their condition and lowering the risk of diabetes complications. Diabetes patients may need to take anti-diabetic medications for the rest of their life in order to manage their blood glucose levels and avoid hypoglycemia and hyperglycemia.
Oral anti-diabetic medications have the advantages of being easier to control and less expensive. As a result, they become a more appealing alternative to insulin, with higher acceptability, which improves treatment adherence. The French health benefit basket is quite important. Diabetes is one of 30 chronic diseases that are fully covered by statutory health insurance (SHI) under the ALD (affections de longue durée) plan. For those who are not covered by ALD, the patient pays a portion of the official health care tariff, which varies based on the type of products and services provided.
Owing to the above factors, the market will likely continue to grow.
The Increasing Diabetes Population in France is Driving the Market.
According to an EU Commission poll, the number of people with chronic diabetes is highest in France, with one in every ten people suffering from the disease. Diabetes is common in France, despite the fact that the guidelines' aim of 80% compliance with recommended healthcare visits is not always fulfilled. To reduce the burden of diabetes, innovative strategies focusing on patient and physician education and information are required to encourage proactive therapy modification and diminish therapeutic inertia.
Because of the disease's increasing incidence, prevalence, and progressive nature, new medications have been developed to give more therapy choices for diabetic patients. Over the last decade, two key kinds of drugs have entered this market: DPP-4 inhibitors and sodium-glucose cotransporter-2 inhibitors (SGLT-2). Oral diabetes medications act in a variety of methods to lower blood sugar levels in persons with type 2 diabetes. Some boost pancreatic insulin secretion, while others enhance cell responsiveness to insulin or inhibit the liver from producing glucose. Others slow glucose absorption after meals.
Because of the disease's increasing incidence, prevalence, and progressive nature, new medications have been developed to give more therapy choices for diabetic patients. The introduction of several new medicines, increased international research partnerships in technological improvement, and increased public awareness of diabetes are some of the key prospects for participants in the France oral anti-diabetes drug market.
Competitive Landscape
France oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence, while the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.
France Oral Anti-Diabetic Drug Industry Leaders
-
Astrazeneca
-
Astellas
-
Sanofi
-
Eli Lilly
-
Janseen
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- May 2023: The French drug safety agency announced it was stepping up monitoring of Ozempic, a diabetes drug promoted by influencers on social networks who flaunt its weight-loss properties. As well as health concerns, the authorities say the increased demand could jeopardize access for legitimate diabetic patients.
- May 2022: Pfizer Inc's diabetes drug resulted in weight loss similar to that of Novo Nordisk's Ozempic in a mid-stage study testing it in patients with type 2 diabetes, according to data published in a medical journal.
France Oral Anti-Diabetic Drug Market Report Scope
Orally administered antihyperglycemic drugs reduce blood glucose levels. They are often used in type 2 diabetes care. France Oral Anti-Diabetic Drug Market is segmented into drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists, Sodium-glucose Cotransport-2 (SGLT-2) inhibitor, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides). The report offers the value (in USD million) and volume (in Units million) for the above segments.
| Biguanides | Metformin |
| Alpha-Glucosidase Inhibitors | Alpha-Glucosidase Inhibitors |
| Dopamine D2 receptor agonist | Bromocriptin |
| SGLT-2 inhibitors | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | |
| Farxiga/Forxiga (Dapagliflozin) | |
| Suglat (Ipragliflozin) | |
| DPP-4 inhibitors | Onglyza (Saxagliptin) |
| Tradjenta (Linagliptin) | |
| Vipidia/Nesina(Alogliptin) | |
| Galvus (Vildagliptin) | |
| Sulfonylureas | Sulfonylureas |
| Meglitinides | Meglitinides |
| Oral Anti-diabetic drugs | Biguanides | Metformin |
| Alpha-Glucosidase Inhibitors | Alpha-Glucosidase Inhibitors | |
| Dopamine D2 receptor agonist | Bromocriptin | |
| SGLT-2 inhibitors | Invokana (Canagliflozin) | |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Suglat (Ipragliflozin) | ||
| DPP-4 inhibitors | Onglyza (Saxagliptin) | |
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina(Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Sulfonylureas | Sulfonylureas | |
| Meglitinides | Meglitinides | |
Key Questions Answered in the Report
What is the current France Oral Anti-Diabetic Drug Market size?
The France Oral Anti-Diabetic Drug Market is projected to register a CAGR of greater than 4% during the forecast period (2025-2030)
Who are the key players in France Oral Anti-Diabetic Drug Market?
Astrazeneca, Astellas, Sanofi, Eli Lilly and Janseen are the major companies operating in the France Oral Anti-Diabetic Drug Market.
What years does this France Oral Anti-Diabetic Drug Market cover?
The report covers the France Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the France Oral Anti-Diabetic Drug Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
France Oral Anti-Diabetic Drug Market Report
Statistics for the 2025 France Oral Anti-Diabetic Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. France Oral Anti-Diabetic Drug analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
